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ABSTRACT - Introduction: The matrix metalloproteinase-7 (MMP-7) gene -181A>G polymorphism 
has been reported to be associated with colorectal cancer (CRC) and gastric cancer (GC) 
susceptibility, yet the results of these previous results have been inconsistent or controversial. 
Aim: To elaborate a meta-analysis to assess the association of -181A>G polymorphism of 
MMP-7 with CRC and GC risk. Methods: Published literature evaluating the association from 
PubMed, Web of Science, Google Scholar and other databases were retrieved up to April 
25, 2018. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using 
random- or fixed-effects model. Results: A total of 19 case-control studies, which included 
eleven studies on CRC (2,169 CRC cases and 2,346 controls) and eight studies on GC (1,545 GC 
cases and 2,366 controls) were identified. There was a significant association between MMP-7 
-181A>G polymorphism and GC risk under the homozygote model (GG vs. AA: OR=1.672, 95% 
CI 1.161-2.409, p=0.006) and the recessive model (GG vs. GA+AA: OR=1.672, 95% CI 1.319-
2.554, p=0.001), but not with CRC. By subgroup analysis based on ethnicity, an increased risk 
of CRC and GC was found only among Asians. Conclusions: This meta-analysis suggests that 
MMP-7 -181A>G polymorphisms is associated with GC risk, but not with CRC. However, our 
results clearly showed that the MMP-7 -181A>G polymorphism significantly increased the risk 
of CRC only in Asians.
RESUMO - Introdução: O polimorfismo da matriz metaloproteinase-7 (MMP-7) -181A>G tem 
sido relatado como associado à suscetibilidade dos cânceres colorretal (CRC) e gástrico (GC), 
mas os resultados desses estudos anteriores foram inconsistentes ou controversos. Objetivo: 
Elaborar metanálise para avaliar a associação do polimorfismo -181A> G da MMP-7 com o 
risco de CRC e GC. Métodos: Revisão da literatura publicada avaliando essa associação no 
PubMed, Web of Science, Google Acadêmico e outras bases de dados até 25 de abril de 
2018. Odds ratio (OR) e o intervalo de confiança de 95% (IC) foram calculados usando dados 
aleatórios ou modelo de efeitos fixos. Resultados: Um total de 19 estudos caso-controle, 
que incluíram 11 trabalhos sobre CRC (2.169 casos de CCR e 2.346 controles) e oito sobre 
GC (1.545 casos de GC e 2.366 controles) foram identificados. Houve associação significativa 
entre o polimorfismo MMP-7 -181A>G e o risco de GC sob o modelo homozigoto (GG vs. AA: 
OR=1,672, IC 95% 1,161-2,409, p=0,006) e o modelo recessivo (GG vs. GA + AA: OR=1,672, IC 
95% 1,319-2,554, p=0,001), mas não com CRC. Por análise de subgrupos com base na etnia, 
um risco aumentado de CRC e GC foi encontrado apenas entre os asiáticos. Conclusões: Esta 
metanálise sugere que os polimorfismos MMP-7 -181A>G estão associados ao risco de GC, 
mas não ao CRC. No entanto, estes resultados mostraram claramente que o polimorfismo 
MMP-7 -181A>G aumentou significativamente o risco de CRC apenas em asiáticos.
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INTRODUCTION
Nowadays, gastrointestinal-related cancers especially gastric cancer (GC) and colorectal cancer (CRC) are major causes of cancer-related death worldwide 7,22,23. Globally, CRC and GC are the third and fourth leading 
cause most common cancers, making up 10% and 7% of cases all new cancer cases, 
respectively 23,27. It is well-known that the development of CRC and GC can be induced 
by the interactions of multiple genetic and environmental factors in complex ways. 
However, the pathogenesis of CRC differs from that of GC in that it is affected by ethnic 
background, regional, life style, environmental factors and molecular pathogenesis27. 
Currently, several genes have been reported to be associated with CRC and GC, and 
the matrix metalloproteinases (MMPs) genes has received increasing attention10, 29,31.
MMPs are classified as a large family of zinc-containing proteases, which 
involved in normal physiological and pathological processes such as degradation and 
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remolding of extracellular matrix, embryonic development, 
reproduction and cancer6,13. MMP-7, the smallest member 
of MMP family, is an endopeptidases with broad substrate 
specificity, which break down extracellular matrix (ECM) by 
degrading macromolecules including casein, type I, II, IV, 
and V gelatins, fibronectin, and proteoglycan18. In addition, 
MMP-7 is one of the main regulatory enzymes involved 
in apoptosis by releases the Fas ligand (FasL) from the 
membrane then induces apoptosis of neighboring cells, or 
decreases cancer-cell apoptosis21. Thus, MMP-7 promotes 
cell survival by resisting apoptosis through cleaving FasL. 
MMP7 is potentially involved in tumor metastasis and 
inflammatory processes10,31.
MMP-7 gene (also known as matrilysin) is localized on 
chromosome 11q21-q22 and contains 13 exons35. The single 
nucleotide polymorphism (SNP) -181A>G in promoter region 
of MMP-7 gene has been considered to be a candidate SNP 
for various conditions including gastrointestinal related 
malignancies1,10,31. There is clear evidence that MMP-7 gene 
up-regulation is significantly related to the promoter activity 
variation of the -181A>G16. Molecular epidemiological 
studies have reported the association of MMP-7 -181A>G 
polymorphism with CRC and GC risk, but the results remain 
conflicting rather than conclusive. Several studies previously 
have performed on the association of MMP-7 -181A>G 
polymorphism with CRC and GC risk10,31.  However, these 
studies had opposite observations and additional case-
control studies with larger sample sizes have been published 
since then. Hence, the association of MMP-7 -181A>G 
polymorphism remains unknown. 
Therefore, we have performed a meta-analysis of all 
eligible studies to derive more precise estimation of the 
association of MMP-7 -181A>G polymorphism with CRC 
and GC risk.
METHODS
Literature search
Following PRISMA guidance, we searched the electronic 
literature databases including PubMed, EMBASE, Elsevier, 
Science Direct, Wan Fang, Chinese National Knowledge 
Infrastructure (CNKI) and Chinese Biomedical Literature 
for all relevant articles published up to April 25, 2018. 
The search strategies were based on combinations of the 
following key words: (‘’matrix metalloproteinase-7’’ OR 
‘’MMP-7’’ OR ‘’matrilysin’’ OR uterine metalloproteinase OR 
‘’pump-1 protease’’ OR ‘’PUMP-1’’) AND (‘’-181A>G OR 
‘’rs11568818’’) AND (‘’colorectal cancer’’ OR ‘’CRC’’) AND 
(‘’gastric adenocarcinoma’’ OR ‘’stomach cancer’’ OR ‘’gastric 
cancer’’ OR ‘’GC’’) AND (‘’gene” or ‘’allele” or ‘’genotype” or 
‘’mutation” or ‘’variant” or ‘’variation” or ‘’polymorphism”), 
without any restriction on language. Review articles were 
hand-searched to find additional eligible studies and only 
published studies with full-text articles were included. We 
excluded studies that were not full-length publications articles 
or letters in peer-reviewed English journals. When the same 
patient population was included in different articles, the 
one with the largest population of participants or the most 
recent one was selected.
Inclusion and exclusion criteria
Inclusion criteria was defined as follows: 1) published 
studies and contained original data; 2) case-control studies; 3) 
evaluating the association of MMP-7 -181A>G polymorphism 
with CRC and GC risk; and 4) sufficient published data 
available to estimate an odds ratio (OR) with 95% confidence 
interval (CI). Major reasons for exclusion of studies were as 
follows: 1) only case population, family based or linkage 
studies; 2) studies that could not offer the number of cases 
and controls or other essential data; 3) reviews, abstracts, 
letters to editor, case reports or animal studies; 4) duplicate 
of previous publication or studies with overlapping patient 
populations; and 5) studies without histologically confirmed 
of CRC and GC. For more than two studies with overlapping 
data, the study with the most subjects or newest published 
data was selected.
Data extraction
Data were carefully extracted from all eligible publications 
by two of the authors independently. If the study provided 
stratum information, the data coming from similar stratum 
were added up to make full use of the data. Disagreements 
between the two authors were resolved by discussing the 
results with a third one. For each study, the following variables 
were collected: first author’s name, year of publication, 
country, ethnicity of participants, number of cases and 
controls, genotyping methods, and allele numbers and 
genotype distributions in cases and controls, minor allele 
frequencies (MAFs) in control subjects, and the results of 
Hardy-Weinberg equilibrium (HWE) test. Different ethnicities 
were categorized as Asian, Caucasian and Latinos (mixed). 
Study designs were stratified to population-based studies 
and hospital-based studies.
Statistical analysis
The strength of the association of MMP-7 -181A>G 
polymorphism with CRC and GC risk was measured using 
odds ratios (ORs) with 95% confidence intervals (CIs). The 
statistical significance of the pooled OR was assessed with 
the Z-test and p<0.05 was considered significant. The 
pooled ORs were performed under five genetic models, 
i.e., allele (G vs. A), heterozygote (GA vs. AA), homozygote 
(GG vs. AA), dominant (GG+GA vs. AA) and recessive (GG vs. 
GA+AA). The between-study heterogeneity was evaluated 
by a chi-square-based Q test, which p value for the Q-test 
less than 0.10 indicates existing heterogeneity among 
studies. In addition, the I2 statistics was used to quantify 
the proportion of the total variation across studies due 
to heterogeneity. A high value of I2 indicated a higher 
probability of the existence of heterogeneity (I2=0% to 25%, 
no heterogeneity; I2=25% to 50%, moderate heterogeneity; 
I2=50% to 75%, large heterogeneity; and I2=75% to 100%, 
extreme heterogeneity). A random-effects (DerSimonian- 
Laird method) or fixed-effects (Mantel-Haenszel method) 
model was used to calculate pooled effect estimates in the 
presence or absence of heterogeneity. HWE of genotype 
distribution in the controls of included studies was conducted 
using by Pearson’s x 2 test, in which p-value less than 0.05 
was considered significantly deviating from HWE. Subgroup 
analyses were performed by ethnicity, genotyping method, 
HWE status, source of controls and cancer type (CRC and GC). 
In addition, to consider the possible sources of heterogeneity, 
the studies we stratified. To validate the reliability of the 
results, sensitivity analysis was performed though omitting 
one case-control study each time, as well as limiting this 
meta-analysis to studies which were conformed to HWE. 
Funnel plots and Egger’s linear regression test were used 
to diagnose potential publication bias (p<0.05). All analyses 
were performed with the comprehensive meta-analysis (CMA) 
2.0 software (Biostat, USA). Two-sided p-values<0.05 were 
considered statistically significant.
RESULTS
Extraction process and study characteristics
The flow diagram of literature search was given in 
Figure 1. The initial search of databases yielded 103 relevant 
publications based on our literature search strategy, and an 
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additional one study was identified through hand searching. 
However, 36 of them were ruled out because of duplicate 
results obtained from multiple databases, 68 articles remained. 
In addition, after the titles and abstracts of the 68 articles 
were reviewed, 49 full-text irrelevant studies were excluded. 
Finally, 19 eligible case-control studies with 3,714 cases 
and 4,712 controls were included in this meta-analysis. 
The characteristics of studies included in the current meta-
analysis are shown in Table 1. Among these studies, eleven 
studies with 2,169 CRC cases and 2,346 controls were on 
CRC2-4,8,16,19,20,24,28,33, and eight studies with 1,545 GC cases and 
2,366 controls were on GC5,11,12,14,15,17,26,34. By ethnics, there 
were 13 studies of Asians (countries: Korea, Japan, China, 
Iran, Kashmir, Taiwan, and India), four studies of Caucasians 
(countries: Italy, France, Poland and Netherland), and two 
studies of Latinos (countries: Brazil and Mexico). According 
to the control source, ten studies were hospital-based, 
eight studies were population-based and one study was not 
clear. The studies used four different genotyping methods 
including direct sequencing, TaqMan, polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP) 
analysis and tetra-primer amplification refractory mutation 
system-polymerase chain (ARMS-PCR). All of the studies 
indicated that the distribution of genotypes in the controls 
was consistent with HWE except for two studies (Table 1).
FIGURE 1 - The study selection and inclusion process.
Quantitative synthesis
Overall study
Table 2 listed the main results of the meta-analysis of 
MMP-7 -181A>G polymorphism with CRC and GC risk. We 
pooled all the 19 case-control studies together to assess 
the overall association of MMP-7 -181A>G polymorphism 
with CRC and GC risk. Overall, no significant main effects 
on CRC and GC susceptibility were observed in the overall 
population under all the five genetic models, i.e., allele (G 
vs. A: OR=1.049, 95% CI 0.889-1.239, p=0.570, Figure 2A), 
heterozygote (GA vs. AA: OR=1.083, 95% CI 0.813-1.443, 
p=0.586), homozygote (GG vs. AA: OR=0.982, 95% CI 0.701-
1.375, p=0.915), dominant (GG+GA vs. AA: OR=1.061, 95% CI 
0.869-1.296, p=559) and recessive (GG vs. GA+AA: OR=1.084, 
95% CI 0.786-1.495, p=0.622).
FIGURE 2 - Forest plot for the association of MMP-7 -181A>G 
polymorphism with CRC and GC risk: A) the allele 
model (G vs. A) in overall estimations; B) the 
homozygote model (GG vs. AA) in GC studies
Colorectal cancer
Table 2 also listed the main results of the meta-analysis 
of MMP-7 -181A>G polymorphism with CRC risk. When all 
the 11 eligible studies were pooled into the meta-analysis 
of MMP-7 -181A>G polymorphism, we have not found 
evidence of a significant MMP-7 -181A>G polymorphism with 
CRC risk under all the five genetic models. In the subgroup 
analysis by ethnicity, significantly increased risk of CRC was 
observed in Asians under three genetic models, i.e., allele (G 
vs. A: OR=0.798, 95% CI 0.661-0.964, p=0.019, Figure 2A), 
homozygote (GG vs. AA: OR=0.490, 95% CI 00.286-0.838, 
p=0.009) and recessive model (GG vs. GA+AA: OR=0.530, 
95% CI 0.340-0.826, p=0.005), but not in Caucasians and 
Latinos populations (Table 2).
We also performed subgroup analyses based on the 
source of control and genotyping method, when it was available 
(Table 3). The hospital-based subgroup analysis revealed 
that the presence of the MMP-7 -181A>G polymorphism 
was related to a higher risk of CRC under the homozygote 
model (GG vs. AA: OR=0.671, 95% CI 0.484-0.951, p=0.023). 
In the PCR-RFLP group, significantly increased association 
between MMP-7 -181A>G polymorphism and CRC risk was 
found under the homozygote model (GG vs. AA: OR=0.680, 
95% CI 0.486-0.950, p=0.024, Table 3).
Gastric cancer
Table 2 also listed the main results of the meta-analysis 
of MMP-7 -181A>G polymorphism with GC risk. There 
was a significant association between MMP-7 -181A>G 
polymorphism and GC risk under two genetic models, i.e., 
homozygote (GG vs. AA: OR=1.672, 95% CI 1.161-2.409, 
p=0.006, Fig 2B) and recessive (GG vs. GA+AA: OR=1.835, 
95% CI 1.319-2.554, p=0.001). Similarly, when stratified by 
ethnicity, a significant association between MMP-7 -181A>G 
polymorphism and increased risk of GC was detected among 
Asians under the homozygote model (GG vs. AA: OR=1.975, 
95% CI 1.331-2.934, p=0.006) and the recessive model (GG 
vs. GA+AA: OR=2.022, 95% CI 1.416-2.886, p=0.001).
The studies were further stratified on the basis of 
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TABLE 1 - Main characteristics of all studies included in the meta-analysis
First Author Country(Ethnicity)
Genotyping
Technique SOC
Case/
Control
Cases Controls
MAFs HWEGenotype Allele Genotype Allele
AA AG GG A G AA AG GG A G
Colorectal 
Cancer
Ghilardi 2003 Italy (Caucasian) Sequencing PB 58/111 15 28 15 58 58 36 61 14 133 89 0.400 0.129
Lievre 2006 France (Caucasian) TaqMan PB 596/565 191 272 131 658 534 187 259 119 1083 497 0.439 0.097
Woo 2007 Korea (Asian) PCR-RFLP PB 185/304 163 22 0 348 22 265 39 0 565 39 0.064 0.232
Ohtani 2009 Japan (Asian) PCR-RFLP HB 119/67 110 9 0 229 9 55 12 0 122 12 0.089 0.420
de Lima 2009 Brazil (Latinos) PCR-RFLP HB 108/113 36 56 16 128 88 41 57 15 139 87 0.384 0.487
Fang 2010 China (Asian) PCR-RFLP PB 252/237 22 30 0 474 30 218 19 0 455 19 0.040 0.520
Dziki 2011 Poland (Caucasian) PCR-RFLP HB 184/205 99 93 52 171 197 66 94 45 216 194 0.473 0.294
Moreno-Ortiz 
2014
México 
(Latinos) PCR-RFLP HB 102/121 46 51 5 143 61 49 54 18 152 90 0.371 0.622
Motoval-Bashi 
2015
Iran 
(Asian) ARMS-PCR NS 61/77 11 31 19 53 69 6 40 31 52 102 0.708 0.156
Banday 2016 Kashmir (Asian) PCR-RFLP HB 142/184 43 82 13 176 108 61 84 39 206 162 0.440 0.317
Yueh 2018 Taiwan (Asian) PCR-RFLP HB 362/362 318 38 6 674 50 311 43 8 665 59 0.081 =0.001
Gastric Cancer
Zhang 2005 China (Asian) PCR-RFLP PB 201/350 167 34 0 368 34 316 33 1 662 35 0.050 0.888
Kubben 2006 Nederland (Caucasian) PCR-RFLP PB 79/169 34 37 8 105 53 46 106 17 198 140 0.414 =0.001
Sugimoto 2008 Japan (Asian) PCR-RFLP HB 160/434 133 27 0 293 27 393 40 1 826 42 0.048 0.986
Li 2008 China (Asian) PCR-RFLP PB 338/380 280 56 2 616 60 342 37 1 721 39 0.051 0.999
Kim 2011 Korea (Asian) PCR-RFLP HB 153/326 128 24 1 280 26 280 45 1 605 47 0.072 0.565
Malik 2011 India (Asian) PCR-RFLP PB 108/195 29 39 40 98 119 63 92 40 218 172 0.441 0.547
Fang 2013 China (Asian) PCR-RFLP HB 246/252 236 10 0 482 10 222 30 0 474 30 0.059 0.315
Kesh 2015 India (Asian) PCR-RFLP HB 260/260 107 108 45 322 198 118 116 26 352 168 0.323 0.746
PCR-RFLP=polymerase chain reaction-restriction fragment length polymorphism; ARMS-PCR=tetra-primer amplification refractory mutation system-polymerase chain; 
SOC=source of control; HB=hospital-based; PB=population-based; MAF=minor allele frequency; HWE=Hardy-Weinberg equilibrium; NS=not stated
source of controls (Table 3). When stratifying by source of 
control, a significant association between MMP-7 -181A>G 
polymorphism and increased risk of GC was detected in 
population-based studies under the recessive model (GG 
vs. GA+AA: OR=1.819, 95% CI 1.173-2.819, p=0.008), and 
in hospital-based studies under two genetic models, i.e., 
homozygote (GG vs. AA: OR=1.884, 95% CI 1.107-3.204, 
p=0.020) and recessive (GG vs. GA+AA: OR=1.858, 95% CI 
1.124-3.069, p=0.016).
Heterogeneity analysis
Heterogeneity was detected among studies under 
all the five genetic models, i.e., allele (G vs. A: I2=70.90%, 
PH=0.001), heterozygote (GA vs. AA: I2=82.36%, PH=0.001), 
homozygote (GG vs. AA: I2=54.65%, PH=0.006), dominant 
(GG+GA vs. AA: I2=65.43%, PH=0.001) and recessive (GG vs. 
GA+AA: I2=65.4%, PH=0.001). Thus, to explore the potential 
sources of heterogeneity across studies, we assessed the 
pooled ORs via stratification by cancer type, ethnicity, 
genotyping method, HWE status and source of controls. The 
results showed that the heterogeneity effectively removed 
by subgroup analyses based on ethnicity among studies on 
CRC. Therefore, we found that genotyping method, HWE 
status and source of controls did not contribute to substantial 
heterogeneity among the meta-analysis.
Sensitivity analysis
To evaluate the effect of individual study on the pooled 
ORs and stability of the meta-analysis results, we excluded 
one study at a time. However, the omission of any single 
study made no significant difference, suggesting that the 
results of this meta-analysis were stable. Moreover, sensitivity 
analysis was performed after excluding HWE-violating studies, 
and the corresponding pooled ORs were not qualitatively 
altered (data not shown).
Publication bias
Both Begg’s funnel plot and Egger’s test were performed 
to assess the publication bias of literature. Begg’s funnel plots 
did not reveal any evidence of obvious asymmetry under all 
five genetic models in the overall meta-analysis. For example, 
the shape of the funnel plot did not indicate any evidence 
of obvious asymmetry under the allele model (Figure 3), and 
the Egger’s test suggested the absence of publication bias 
(PBeggs=0.293 and PEggers=0.483). However, the results 
of Egger’s regression test showed evidence of publication 
bias among Caucasian’s studies on CRC under the recessive 
model (GG vs. GA+AA: PBegg’s=0.296, PEggers=0.001).
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TABLE 2 - Meta-analysis for the association of MMP-7 -181A>G polymorphism with CRC and GC risk
Subgroup Genetic model Type of model
Heterogeneity Odds ratio (OR) Publication bias
I2 (%) PH OR 95% CI ZOR POR PBeggs PEggers
Overall (n=19) G vs. A Random 70.90 =0.001 1.049 0.889-1.239 0.568 0.570 0.293 0.483
 GA vs. AA Random 82.36 =0.001 1.083 0.813-1.443 0.545 0.586 0.293 0.906
 GG vs. AA Random 54.65 0.006 0.982 0.701-1.375 -0.107 0.915 0.766 0.611
 GG+GA vs. AA Random 65.43 =0.001 1.061 0.869-1.296 0.585 0.559 0.068 0.223
 GG vs. GA+AA Random 60.48 0.001 1.084 0.786-1.495 0.494 0.622 0.692 0.651
Colorectal 
cancer (n=11) G vs. A Random 58.32 0.008 0.947 0.791-1.133 -0.593 0.553 0.275 0.345
 GA vs. AA Random 85.27 =0.001 1.101 0.721-1.682 0.444 0.657 0.876 0.779
 GG vs. AA Random 58.51 0.018 0.791 0.529-1.183 -1.142 0.253 0.536 0.330
 GG+GA vs. AA Fixed 42.24 0.068 1.032 0.894-1.192 0.431 0.667 0.533 0.355
 GG vs. GA+AA Random 68.09 0.003 0.878 0.589-1.309 -0.639 0.523 0.901 0.401
Gastric cancer 
(n=8) G vs. A Random 76.10 =0.001 1.215 0.897-1.645 1.256 0.209 0.901 0.459
 GA vs. AA Random 79.18 =0.001 1.063 0.711-1.590 0.300 0.764 0.035 0.233
 GG vs. AA Fixed 0.00 0.485 1.672 1.161-2.409 2.763 0.006 0.229 0.499
 GG+GA vs. AA Random 78.48 =0.001 1.132 0.771-1.660 0.632 0.527 0.107 0.222
 GG vs. GA+AA Fixed 0.00 0.789 1.835 1.319-2.554 3.604 =0.001 0.367 0.310
Colorectal Cancer 
Asian (n=6) G vs. A Fixed 47.83 0.088 0.798 0.661-0.964 -2.337 0.019 0.707 0.796
 GA vs. AA Random 91.80 =0.001 1.216 0.486-3.040 0.416 0.676 0.707 0.959
 GG vs. AA Fixed 0.00 0.612 0.490 0.286-0.838 -2.606 0.009 1.000 0.995
 GG+GA vs. AA Fixed 46.52 0.096 0.896 0.708-1.134 -0.915 0.360 0.707 0.189
 GG vs. GA+AA Fixed 0.00 0.397 0.530 0.340-0.826 -2.808 0.005 1.000 0.587
Caucasian (n=3) G vs. A Fixed 40.68 0.185 1.123 0.981-1.285 1.676 0.094 0.296 0.126
 GA vs. AA Fixed 38.97 0.194 0.923 0.744-1.143 -0.736 0.461 1.000 0.844
 GG vs. AA Fixed 59.28 0.086 1.054 0.812-1.366 0.393 0.694 1.000 0.643
 GG+GA vs. AA Fixed 53.13 0.118 1.180 0.960-1.451 1.569 0.117 1.000 0.460
 GG vs. GA+AA Fixed 51.03 0.130 1.210 0.962-1.522 1.628 0.104 0.296 0.001
Latinos (n=2) G vs. A Fixed 55.62 0.133 0.897 0.681-1.181 -0.773 0.440 NA NA
 GA vs. AA Fixed 0.00 0.795 1.059 0.709-1.581 0.278 0.781 NA NA
 GG vs. AA Random 75.98 0.041 0.625 0.157-2.488 -0.667 0.505 NA NA
 GG+GA vs. AA Fixed 0.00 0.476 0.947 0.645-1.392 -0.276 0.783 NA NA
 GG vs. GA+AA Random 76.58 0.039 0.606 0.162-2.267 -0.743 0.457 NA NA
Gastric Cancer  
Asian (n=7) G vs. A Random 69.58 0.003 1.331 0.994-1.782 1.918 0.055 1.000 0.451
 GA vs. AA Random 74.59 0.001 1.197 0.815-1.758 0.917 0.359 0.229 0.368
 GG vs. AA Fixed 0.00 0.976 1.976 1.331-2.934 3.380 0.001 0.259 0.298
 GG+GA vs. AA Random 71.98 0.002 1.281 0.898-1.826 1.367 0.172 0.367 0.341
 GG vs. GA+AA Fixed 0.00 0.953 2.022 1.416-2.886 3.877 =0.001 0.259 0.240
NA=not applicable
TABLE 3 - Meta-analysis for the association of MMP-7 -181A>G polymorphism with CRC and GC risk
Subgroup Genetic model Type of model
Heterogeneity Odds ratio (OR) Publication bias
I2 (%) PH OR 95% CI ZOR POR PBeggs PEggers
Colorectal Cancer  
PB (n=4) G vs. A Fixed 21.99 0.279 1.089 0.943-1.257 1.159 0.246 0.734 0.390
 GA vs. AA Random 94.02 =0.001 1.961 0.660-5.829 1.211 0.226 0.308 0.456
 GG vs. AA Fixed 65.72 0.088 1.178 0.871-1.595 1.063 0.288 NA NA
 GG+GA vs. AA Fixed 0.00 0.518 1.089 0.890-1.333 0.829 0.407 0.308 0.414
 GG vs. GA+AA Fixed 71.99 0.059 1.153 0.885-1.503 1.054 0.292 NA NA
HB (n=6) G vs. A Random 59.11 0.032 0.884 0.688-1.135 -0.969 0.333 0.060 0.118
 GA vs. AA Fixed 45.41 0.103 0.892 0.720-1.106 -1.039 0.299 1.000 0.585
 GG vs. AA Fixed 25.38 0.250 0.671 0.484-0.951 -2.260 0.023 0.806 0.583
 GG+GA vs. AA Random 56.09 0.044 0.971 0.701-1.347 -0.174 0.862 0.707 0.192
 GG vs. GA+AA Random 73.18 0.005 0.702 0.367-1.341 -1.072 0.284 0.806 0.258
PCR-RFLP (n=8) G vs. A Random 52.42 0.040 0.934 0.751-1.160 -0.620 0.536 0.386 0.396
 GA vs. AA Random 89.23 =0.001 1.212 0.665-2.210 0.627 0.531 0.386 0.423
 GG vs. AA Fixed 25.41 0.252 0.680 0.486-0.950 -2.261 0.024 0.806 0.583
 GG+GA vs. AA Fixed 47.45 0.065 1.022 0.785-1.331 0.165 0.869 0.901 0.260
 GG vs. GA+AA Random 73.18 0.005 0.702 0.367-1.341 -1.072 0.284 0.806 0.258
Gastric Cancer  
PB (n=4) G vs. A Random 77.98 0.003 1.360 0.884-2.093 1.401 0.161 0.734 0.873
 GA vs. AA Random 83.08 =0.001 1.138 0.601-2.155 0.397 0.692 0.089 0.192
 GG vs. AA Fixed 39.16 0.177 1.504 0.911-2.484 1.595 0.111 0.734 0.678
 GG+GA vs. AA Random 81.36 0.001 1.244 0.693-2.233 0.733 0.464 0.089 0.239
 GG vs. GA+AA Fixed 0.00 0.400 1.819 1.173-2.819 2.673 0.008 0.734 0.490
HB (n=4) G vs. A Random 80.17 0.002 1.048 0.622-1.766 0.178 0.859 0.734 0.478
 GA vs. AA Random 80.40 0.002 0.985 0.545-1.781 -0.049 0.961 0.734 0.576
 GG vs. AA Fixed 0.00 0.918 1.884 1.107-3.204 2.336 0.020 0.296 0.644
 GG+GA vs. AA Random 81.01 0.001 1.016 0.564-1.831 0.054 0.957 0.308 0.475
 GG vs. GA+AA Fixed 0.00 0.901 1.858 1.124-3.069 2.417 0.016 0.296 0.621
PB=population-based; HB=hospital-based; PCR-RFLP=polymerase chain reaction-restriction fragment length polymorphism; NA= not applicable
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FIGURE 3 - Begg’s funnel plots of the MMP-7 -181A>G 
polymorphism with CRC and GC risk for publication 
bias test under the allele model (G vs. A): each 
point represents a separate study for the indicated 
association
Minor allele frequencies (MAFs)
The minor allele frequencies (MAFs) of the MMP-7 -181A>G 
polymorphism are shown in Table 2. The allele and genotype 
distributions of MMP-7 -181A>G polymorphism exhibited 
ethnic variations. The MMP-7 -181A>G polymorphism MAF in 
overall populations, Asians, Caucasians and Latinos were 37.4% 
(4.0%-70.8%), 37.4% (4.0%-70.8%), 43.65% (40.0%-47.30%), 
and 37.75% (37.1%-38.4%), respectively.
DISCUSSION
MMP-7 gene is implicated in cancer susceptibility and 
metastasis in a variety of gastrointestinal-related cancers 19, 
11. In the recent decade, several molecular epidemiological 
studies have been performed to assess the association of 
MMP-7 -181A>G polymorphism with CRC and GC risk. 
However, the results were conflicting. Thus, we conducted 
a comprehensive meta-analysis involving published data, 
to assess the strength of association of MMP-7 -181A>G 
polymorphism CRC and GC risk. In current meta-analysis, a 
total of 19 case-control studies including 3,714 cases and 
4,712 controls were recruited. The subgroup analysis by cancer 
type, showed that there was significant association between 
the MMP-7 -181A>G polymorphism and increased risk of 
GC in overall estimations, but not with CRC. In a stratified 
analysis by ethnicity, our results indicated that MMP-7 
-181A>G polymorphism was associated with a significantly 
increased risk of CRC and GC in Asians. Moreover, stratified 
analysis according to source of controls and genotyping 
method revealed a significantly increased risk of CRC and 
GC in participants with the MP-7 -181A>G polymorphism 
in those studies involving PCR-RFLP, population-based and 
hospital-based (Table 3).
Our results were consistent with the previous meta-
analyses on MMP-7 -181A>G polymorphism and GC risk. 
Thus, MMP-7 -181A>G polymorphism might serve as a 
susceptibility marker to GC risk. However, our results are 
inconsistent with the previous meta-analyses on MMP-7 
-181A>G polymorphism and CRC risk. In 2013, two meta-
analyses by Ke et al and Yang et al were conducted to examine 
the association between MMP-7 -181A>G polymorphism 
and CRC risk 10,31. Ke et al in meta-analysis of seven case-
control have found a significant association between MMP-7 
-181A>G polymorphism and CRC under the homozygote 
model (GG vs. AA, OR=1.13, 95% CI=1.01-1.26) 10. Similarly, 
Yang et al in a meta-analysis of seven studies with 1,502 
CRC cases and 1,602 controls found significant association 
between MMP-7 -181A>G polymorphism and CRC under the 
homozygote model (OR=1.31, 95% CI 1.02-1.69) 31. However, 
their findings about MMP-7 -181A>G polymorphism and 
CRC risk essentially remains an open field, as the number of 
studies is considerably smaller than that needed to yield a 
robust conclusion. In addition, the previous meta-analyses 
did not perform stratified analysis by ethnicity to identify 
possible association of MMP-7 -181A>G polymorphism with 
CRC among different ethnic groups.
Between-studies heterogeneity plays an important role 
when performing a meta-analysis 32. Heterogeneity could 
result from study design, genotyping error, selection bias, 
population stratification, sample size, allelic heterogeneity, or 
chance 9,25. Therefore, finding the source of heterogeneity is 
very important for the final result of meta-analysis. Through 
performing sub group analysis, we found that the heterogeneity 
could not be explained by genotyping method, HWE status 
and source of controls in this meta-analysis. However, the 
results showed that the heterogeneity effectively removed 
by subgroup analysis based on ethnicity among studies 
on CRC, indicating that studies among Asian populations 
regarding CRC might be a source of the heterogeneity in 
our meta-analysis.
This meta-analysis had three main strengths. First, 
this is the biggest and most recent meta-analysis of the 
association of MMP-7 -181A>G polymorphism with CRC 
and GC risk, and it was more powerful than previous single 
case-control studies. Second, this is the first meta-analysis 
by subgroup analysis showed that the MMP-7 -181A>G 
polymorphism was associated with CRC risk in Asians. Third, 
a comprehensive searching strategy from several electronic 
databases with manual search made the eligible studies 
included as much as possible.
Despite the clear strengths of this meta-analysis, 
limitations of our meta-analysis should be noted. First, 
although all the eligible studies were included to this meta-
analysis, the sample size of the included studies was not 
large enough, which could increase the likelihood of type I 
and type II errors. Therefore, there was a lack of statistical 
power to better evaluate the association of MMP-7 -181A>G 
polymorphism with CRC and GC risk. Second, most of included 
studies in the present meta-analysis mainly provided data in 
Asians. In addition, the sample size was relatively small for 
stratified analyses by ethnicity and might not have provided 
sufficient power to estimate the association of MMP-7 -181A>G 
polymorphism among different ethnic groups. Third, although 
the funnel plot and Egger’s test did not show evidence of 
publication bias in overall estimations, the influence of bias 
in the present analysis could not be completely excluded. 
For example, the negative findings are usually difficult to get 
published, or in this meta-analysis we have included only 
studies published in English, which produced selection bias 
at the start of our study. Fourth, the present meta-analysis 
was based primarily on unadjusted effect estimates, because 
most studies did not provide the adjusted OR and 95%CI 
controlling for potential confounding factors, thus the effect 
estimates were relatively imprecise. If individual data were 
available, adjusted ORs could be obtained to give a more 
precise analysis. Finally, it is well known that CRC and GC are 
multifactor conditions; however, the effects of gene-gene 
and gene-environment interactions were not addressed in 
the current meta-analysis.
CONCLUSION
This meta-analysis indicated that the MMP-7 -181A>G 
polymorphism might be a risk factor for susceptibility to GC in 
overall estimations and in Asians. However, our results clearly 
showed that the MMP-7 -181A>G polymorphism significantly 
increased the risk of CRC only in Asians. Considering the limited 
sample size and ethnicities, well-designed studies taking into 
consideration of gene-gene and gene-environment interactions 
should be performed to confirm our results.
Review ARticle
6/7 ABCD Arq Bras Cir Dig 2019;32(3):e1449
ORCID
Hossein Neamatzadeh: 0000-0003-1031-9288
REFERENCES
1. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution 
of matrilysin (MMP-7) to the metastatic pathway of human colorectal 
cancers. Gut. 1999 Aug 1;45(2):252–8.
2. Banday MZ, Sameer AS, Mir AH, Mokhdomi TA, Chowdri NA, Haq E. 
Matrix metalloproteinase (MMP) -2, -7 and -9 promoter polymorphisms 
in colorectal cancer in ethnic Kashmiri population — A case–control 
study and a mini review. Gene. 2016 Sep 1;589(1):81–9.
3. Dziki Ł, Przybyłowska K, Majsterek I, Trzciński R, Mik M, Sygut A. A/G 
Polymorphism of the MMP-7 Gene Promoter Region in Colorectal 
Cancer. Polish J Surg. 2011 Jan 1;83(11):622–6.
4. Fang W-L, Liang W-B, He H, Zhu Y, Li S-L, Gao L-B, et al. Association of 
Matrix Metalloproteinases 1, 7, and 9 Gene Polymorphisms with Genetic 
Susceptibility to Colorectal Carcinoma in a Han Chinese Population. DNA 
Cell Biol. 2010 Nov;29(11):657–61.
5. Fang W-L, Liang W-B, Gao L-B, Zhou B, Xiao F-L, Zhang L. Genetic 
polymorphisms in Matrix Metalloproteinases -1 and -7 and susceptibility 
to gastric cancer: an association study and meta-analysis. Iran J Allergy 
Asthma Immunol. 2013 Jul 9;12(3):203–10.
6. Fanjul-Fernández M, Folgueras AR, Cabrera S, López-Otín C. Matrix 
metalloproteinases: Evolution, gene regulation and functional analysis 
in mouse models. Biochim Biophys Acta - Mol Cell Res. 2010 Jan 
1;1803(1):3–19.
7. Forat-Yazdi M, Gholi-Nataj M, Neamatzadeh H, Nourbakhsh P, Shaker-
Ardakani H. Association of XRCC1 Arg399Gln polymorphism with 
colorectal cancer risk: A huge meta analysis of 35 studies. Asian Pacific 
J Cancer Prev [Internet]. 2015;16(8).
8. Ghilardi G, Biondi ML, Erario M, Guagnellini E, Scorza R. Colorectal 
carcinoma susceptibility and metastases are associated with matrix 
metalloproteinase-7 promoter polymorphisms. Clin Chem. 2003 
Nov;49(11):1940–2.
9. Gohari M, Neámatzadeh H, Jafari MA, Mazaheri M, Zare-Shehneh M, 
Abbasi-Shavazi E. Association between the p53 codon 72 polymorphism 
and primary open-angle glaucoma risk: Meta-analysis based on 11 
case-control studies. Indian J Ophthalmol. 2016 Oct;64(10):756–61.
10. Ke P, Wu Z-D, Wen H-S, Ying M-X, Long H-C, Qing L-G. Current evidence 
on associations between the MMP-7 (-181A&gt;G) polymorphism and 
digestive system cancer risk. Asian Pac J Cancer Prev. 2013;14(4):2269–72.
11. Kesh K, Subramanian L, Ghosh N, Gupta V, Gupta A, Bhattacharya S, et 
al. Association of MMP7 −181A→G Promoter Polymorphism with Gastric 
Cancer Risk. J Biol Chem. 2015 Jun 5;290(23):14391–406.
12. Kim JH, Pyun JA, Lee KJ, Cho SW, Kwack KB. [Study on association between 
single nucleotide polymorphisms of MMP7, MMP8, MMP9 genes and 
development of gastric cancer and lymph node metastasis]. Korean J 
Gastroenterol. 2011 Nov 25;58(5):245–51.
13. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. 
Amino Acids. 2011 Jul;41(2):271–90. 
14. Kubben FJGM, Sier CFM, Meijer MJW, van den Berg M, van der Reijden JJ, 
Griffioen G, et al. Clinical impact of MMP and TIMP gene polymorphisms 
in gastric cancer. Br J Cancer. 2006 Sep 29;95(6):744–51.
15. Li J, Tian M, Zhao A. T2028 Polymorphism in the Promoter Region of the 
Metalloproteinase-7 Increases Susceptibility and Risk of Metastasis of 
Gastric Adenocarcinoma. Gastroenterology. 2008 Apr 1;134(4):A-603.
16. Lièvre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, et al. Genetic 
polymorphisms of MMP1, MMP3 and MMP7gene promoter and risk 
of colorectal adenoma. BMC Cancer. 2006 Dec 24;6(1):270.
17. Malik MA, Zargar SA, Mittal B. Role of the metalloproteinase-7 (181A&gt;G) 
polymorphism in gastric cancer susceptibility: a case control study in 
Kashmir valley. Asian Pac J Cancer Prev. 2011;12(1):73–6.
18. Mittal R, Patel AP, Debs LH, Nguyen D, Patel K, Grati M, et al. Intricate 
Functions of Matrix Metalloproteinases in Physiological and Pathological 
Conditions. J Cell Physiol. 2016 Dec 1;231(12):2599–621.
19. Moreno-Ortiz JM, Gutierrez-Angulo M, Partida-Pérez M, Peregrina-
Sandoval J, Ramírez-Ramírez R, Muñiz-Mendoza R, et al. Association of 
MMP7-181A/G and MMP13-77A/G polymorphisms with colorectal cancer 
in a Mexican population. Genet Mol Res. 2014 Feb 14;13(2):3537–44.
20. Motovali-Bashi M, Sadeghi Z, Hemati S. Relationship between -181 (A/G) 
region single nucleotide polymorphisms of matrilysin gene promoter 
and the onset and prevalence of colorectal cancer using tetra-primer 
ARMS PCR and RFLP-PCR techniques [Internet]. Vol. 7, Basic & Clinical 
Cancer Research. Tehran University of Medical Sciences, Cancer Institute 
of Iran, Cancer Research Center; 2015. 20-31.
21. Musiał K, Zwolińska D. Matrix metalloproteinases and soluble Fas/FasL 
system as novel regulators of apoptosis in children and young adults 
on chronic dialysis. Apoptosis. 2011 Jul;16(7):653–9.
22. Namazi A, Forat-Yazdi M, Jafari MA, Foroughi E, Farahnak S, Nasiri R, et 
al. Association between polymorphisms of ERCC5 gene and susceptibility 
to gastric cancer: A systematic review and meta-analysis. Asian Pacific 
J Cancer Prev. 2017;18(10).
23. Namazi A, Forat-Yazdi M, Jafari M, Farahnak S, Nasiri R, Foroughi E, et 
al. Association of interleukin-10 -1082 A/G (rs1800896) polymorphism 
with susceptibility to gastric cancer: meta-analysis of 6,101 cases and 
8,557 controls. Arq Gastroenterol. 2018 Mar;55(1):33–40.
24. Ohtani H, Maeda N MY. Functional polymorphisms in the promoter 
regions of matrix metalloproteinase-2,-3,-7,-9 and TNF- alpha genes, 
and the risk of colorectal neoplasm in Japanese. Yonago Acta Med. 
2009;52:47–56.
25. Sobhan MR, Mahdinezhad-Yazdi M, Aghili K, Zare-Shehneh M, Rastegar 
S, Sadeghizadeh-Yazdi J, et al. Association of TNF-α-308 G &gt; A and 
−238G &gt; A polymorphisms with knee osteoarthritis risk: A case-control 
study and meta-analysis. J Orthop. 2018 Sep 1;15(3):747–53.
26. Sugimoto M, Furuta T, Kodaira C, Nishino M, Yamade M, Ikuma M, 
et al. Polymorphisms of matrix metalloproteinase-7 and chymase are 
associated with susceptibility to and progression of gastric cancer in 
Japan. J Gastroenterol. 2008 Oct 29;43(10):751–61.
27. Tak DH, Moon HS, Kang SH, Sung JK, Jeong HY. Prevalence and Risk 
Factors of Gastric Adenoma and Gastric Cancer in Colorectal Cancer 
Patients. Gastroenterol Res Pract. 2016 Dec 26;2016:1–7.
28. Woo M, Park K, Nam J, Kim JC. Clinical implications of matrix metalloproteinase-1, 
-3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms 
in colorectal cancer. J Gastroenterol Hepatol. 2007 Jul;22(7):1064–70.
29. Wu J, Guan X, Li Y-T, Bai P, Wu J. Matrix metalloproteinase7 -181A/G 
polymorphism is associated with increased cancer risk among high-
quality studies: Evidence from a meta-analysis. Clin Biochem. 2013 
Nov;46(16–17):1649–54.
30. Yang T-F, Guo L, Wang Q. Meta-analysis of associations between four 
polymorphisms in the matrix metalloproteinases gene and gastric cancer 
risk. Asian Pac J Cancer Prev. 2014;15(3):1263–7.
31. Yang X, Liu Y, Yang Y, Li B. Update meta-analysis on MMP-7 −181A&gt;G 
polymorphism and cancer risk: Evidence from 25 studies. Gene. 2013 
Jun 1;521(2):252–8.
32. Yazdi MM, Jamalaldini MH, Sobhan MR, Jafari M, Mazaheri M, Zare-
Shehneh M, et al. Association of ESRα Gene Pvu II T>C, XbaI A>G and 
BtgI G>A Polymorphisms with Knee Osteoarthritis Susceptibility: A 
Systematic Review and Meta-Analysis Based on 22 Case-Control Studies. 
Arch bone Jt Surg. 2017 Nov;5(6):351–62.
33. Yueh T-C, Wu C-N, Hung Y-W, Chang W-S, Fu C-K, Pei J-S, et al. The 
Contribution of MMP-7 Genotypes to Colorectal Cancer Susceptibility 
in Taiwan. Cancer Genomics Proteomics. 2018 Apr 24;15(3):207–12.
34. Zhang J, Jin X, Fang S, Wang R, Li Y, Wang N, et al. The functional 
polymorphism in the matrix metalloproteinase-7 promoter increases 
susceptibility to esophageal squamous cell carcinoma, gastric cardiac 
adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis. 
2005 Oct 1;26(10):1748–53.
35. Zhang Y, Chen Q. Relationship between matrix metalloproteinases and 
the occurrence and development of ovarian cancer. Brazilian J Med Biol 
Res = Rev Bras Pesqui medicas e Biol. 2017 May 18;50(6):e6104.
ASSOciAtiON OF MMP-7 -181A>G POlYMORPHiSM witH cOlORectAl cANceR AND GAStRic cANceR SUScePtiBilitY: A SYSteMAtic Review AND MetA-ANAlYSiS
7/7ABCD Arq Bras Cir Dig 2019;32(3):e1449
